The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
The 118 A > G polymorphism in the human µ‐opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease
Abstract
Background: Dispositions for genes encoding opioid receptors may explain some variability in morphine efficacy. Experimental studies show that morphine and morphine‐6‐glucuronide are less effective in individuals carrying variant alleles caused by the 118 A > G polymorphism in the µ‐opioid receptor gene (OPRM1). The purpose of the study was to investigate whether this and other genetic polymorphisms in OPRM1 influence the efficacy of morphine in cancer pain patients. Methods: We screened 207 cancer pain patients on oral morphine treatment for four frequent OPRM1 gene polymorphisms. The polymorphisms were the −172 G > T polymorphism in the 5′untranslated region of exon 1, the 118 A > G polymorphism in exon 1, and the IVS2 + 31 G > A and IVS2 + 691 G > C polymorphisms, both in intron 2. Ninety‐nine patients with adequately controlled pain were included in an analysis comparing morphine doses and serum concentrations of morphine and morphine metabolites in the different genotypes for the OPRM1 polymorphisms. Results: No differences related to the −172 G > T, the IVS2 + 31 G > A and the IVS2 + 691 G > C polymorphisms were observed. Patients homozygous for the variant G allele of the 118 A > G polymorphism (n = 4) needed more morphine to achieve pain control, compared to heterozygous (n = 17) and homozygous wild‐type (n = 78) individuals. This difference was not explained by other factors such as duration of morphine treatment, performance status, time since diagnosis, time until death, or adverse symptoms. Conclusion: Patients homozygous for the 118 G allele of the µ‐opioid receptor need higher morphine doses to achieve pain control. Thus, genetic variation at the gene encoding the µ‐opioid receptor contributes to variability in patients' responses to morphine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Self-citationKarnofsky, D. A., Abelmann, W. H., Craver, L. F., & Burchenal, J. H. (1948) · Cancer · doi:10.1002/1097-0142(194811)1:4<634::aid-cncr2820010410>3.0.co;2-l · Cited by 2,248
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562 · cited 4×
“The BPI is developed for the use in cancer pain patients, is validated in Norwegian, and is recommended by the European Association of Palliative Care for use in clinical studies (12, 13, 15).”
BackgroundMethodInfluentialSerlin, R. C., Mendoza, T. R., Nakamura, Y., Edwards, K. R., & Cleeland, C. S. (1995) · Pain · doi:10.1016/0304-3959(94)00178-h · Cited by 1,494
The LightCycler TM : A Microvolume Multisample Fluorimeter with Rapid Temperature Control
Wittwer, C. T., Ririe, K. M., Andrew, R. V., David, D. A., Gundry, R. A., & Balis, U. J. (1997) · BioTechniques · doi:10.2144/97221pf02 · Cited by 893
Pain Measurement Tools and Methods in Clinical Research in Palliative Care
Caraceni, A., Cherny, N., Fainsinger, R., Kaasa, S., Poulain, P., Radbruch, L., & De Conno, F. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(01)00409-2 · Cited by 426
Self-citationOpioid rotation for toxicity reduction in terminal cancer patients
de Stoutz, N. D., Bruera, E., & Suarez-Almazor, M. (1995) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(95)90924-c · Cited by 382
Morphine-6-glucuronide, a potent mu agonist
Pasternak, G. W., Bodnar, R. J., Clark, J. A., & Inturrisi, C. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90431-0 · Cited by 361
The Norwegian Brief Pain Inventory Questionnaire
Klepstad, P., Loge, J. H., Borchgrevink, P. C., Mendoza, T. R., Cleeland, C. S., & Kaasa, S. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00526-2 · Cited by 313
Self-citationHoehe, M. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2895 · Cited by 290
Mercadante, S., Casuccio, A., Fulfaro, F., Groff, L., Boffi, R., Villari, P., Gebbia, V., & Ripamonti, C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2898 · Cited by 250
Skarke, C., Darimont, J., Schmidt, H., Geisslinger, G., & Lötsch, J. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2003.5 · Cited by 226
Incomplete cross tolerance and multiple mu opioid peptide receptors
Pasternak, G. W. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01616-3 · Cited by 213
Lötsch, J., Skarke, C., Grösch, S., Darimont, J., Schmidt, H., & Geisslinger, G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200201000-00002 · Cited by 211
Oral morphine in cancer pain: influences on morphine and metabolite concentration
McQuay, H. J., Carroll, D., Faura, C. C., Gavaghan, D. J., Hand, C. W., & Moore, R. A. (1990) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1990.145 · Cited by 167
Opioid receptor and peptide gene polymorphisms: potential implications for addictions
LaForge, K. S., Yuferov, V. P., & Kreek, M. J. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00819-0 · Cited by 167
Lötsch, J., Zimmermann, M., Darimont, J., Marx, C., Dudziak, R., Skarke, C., & Geißlinger, G. (2002) · Anesthesiology · doi:10.1097/00000542-200210000-00011 · Cited by 155
Klepstad, P., Kaasa, S., & Borchgrevink, P. C. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050003 · Cited by 88
Self-citationKlepstad, P., Borchgrevink, P. C., Dale, O., Zahlsen, K., Aamo, T. O., Fayers, P. M., Fougner, B., & Kaasa, S. (2003) · Palliative Medicine · doi:10.1191/0269216303pm835oa · Cited by 58
Self-citationKlepstad, P., Dale, O., Kaasa, S., et al. (2003) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2003.00138.x · Cited by 55
Self-citation
Cited by
Opioid dependence and addiction during opioid treatment of chronic pain
Ballantyne, J. C., & LaForge, S. K. (2007) · Pain · doi:10.1016/j.pain.2007.03.028 · Cited by 447
Rakvåg, T. T., Klepstad, P., Baar, C., Kvam, T.-M., Dale, O., Kaasa, S., Krokan, H. E., & Skorpen, F. (2005) · Pain · doi:10.1016/j.pain.2005.03.032 · Cited by 347
Self-citationAssociation of ABCB1/MDR1 and OPRM1 Gene Polymorphisms With Morphine Pain Relief
Campa, D., Gioia, A., Tomei, A., Poli, P., & Barale, R. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100385 · Cited by 345
Somogyi, A. A., Barratt, D. T., & Coller, J. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100095 · Cited by 324
Chou, W.-Y., Wang, C.-H., Liu, P.-H., Liu, C.-C., Tseng, C.-C., & Jawan, B. (2006) · Anesthesiology · doi:10.1097/00000542-200608000-00016 · Cited by 315
Metadata
- Authors
- Klepstad, P., Rakvåg, T. T., Kaasa, S., Holthe, M., Dale, O., Borchgrevink, P. C., Baar, C., Vikan, T., Krokan, H. E., & Skorpen, F.
- Venue
- Acta Anaesthesiologica Scandinavica
- Publisher
- Wiley
- Published
- 2004-10-25
- Volume
- 48
- Issue
- 10
- Pages
- 1232-1239
- ISSN
- 0001-5172 (ISSN-L)
- 1399-6576
- OpenAlex
- W2022797906
- Cited by
- 381
- References
- 21
- FWCI
- 20.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.